Last reviewed · How we verify
Maintenance of Healing Erosive Esophagitis — Treatment Landscape & Competitive Intelligence
9 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Dexilant | DEXLANSOPRAZOLE | Takeda | Proton Pump Inhibitor [EPC] | (H+, K+)-ATPase | 2009-01-01 | |
| Nexium | esomeprazole | AstraZeneca | Proton pump inhibitor (PPI) | Potassium-transporting ATPase | 2001-02-20 | |
| Protonix | pantoprazole | Generic (originally Byk Gulden/Altana/Nycomed) | Proton pump inhibitor (PPI) | ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1 | 2000-02-02 | |
| Pantoprazole Sodium | Pantoprazole Sodium | Pfizer | Proton pump inhibitor (PPI) | (H+, K+)-ATPase enzyme | 2000-01-01 | |
| Prilosec | omeprazole | AstraZeneca (originally Astra AB) | Proton pump inhibitor (PPI) | ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19 | 1989-09-14 | |
| Dexilant | Dexilant | Genuine Research Center, Egypt | Sterile alpha and TIR motif-containing protein 1, Cytosolic endo-beta-N-acetylglucosaminidase, Potassium-transporting ATPase | |||
| Omeprazol | Omeprazol | RenJi Hospital | ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19 | |||
| Pantoprazol | Pantoprazol | Northern Orthopaedic Division, Denmark | ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1 | |||
| Dexlan | Dexlan | Chang Gung Memorial Hospital | Sterile alpha and TIR motif-containing protein 1, Cytosolic endo-beta-N-acetylglucosaminidase, Potassium-transporting ATPase |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Maintenance of Healing Erosive Esophagitis
- AstraZeneca · 1 drug in Maintenance of Healing Erosive Esophagitis
- AstraZeneca (originally Astra AB) · 1 drug in Maintenance of Healing Erosive Esophagitis
- Chang Gung Memorial Hospital · 1 drug in Maintenance of Healing Erosive Esophagitis
- Generic (originally Byk Gulden/Altana/Nycomed) · 1 drug in Maintenance of Healing Erosive Esophagitis
- Genuine Research Center, Egypt · 1 drug in Maintenance of Healing Erosive Esophagitis
- Northern Orthopaedic Division, Denmark · 1 drug in Maintenance of Healing Erosive Esophagitis
- Pfizer · 1 drug in Maintenance of Healing Erosive Esophagitis
- RenJi Hospital · 1 drug in Maintenance of Healing Erosive Esophagitis
- Takeda · 1 drug in Maintenance of Healing Erosive Esophagitis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Maintenance of Healing Erosive Esophagitis:
- Maintenance of Healing Erosive Esophagitis treatment updates — RSS
- Maintenance of Healing Erosive Esophagitis treatment updates — Atom
- Maintenance of Healing Erosive Esophagitis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Maintenance of Healing Erosive Esophagitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/maintenance-of-healing-erosive-esophagitis. Accessed 2026-06-10.
Related
- Maintenance of Healing Erosive Esophagitis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing